Literature DB >> 24199592

Immortalized human fetal bone marrow-derived mesenchymal stromal cell expressing suicide gene for anti-tumor therapy in vitro and in vivo.

Wayne Y W Lee1, Ting Zhang, Carol P Y Lau, C C Wang, Kai-Ming Chan, Gang Li.   

Abstract

BACKGROUND AIMS: Cancer is one of the greatest health challenges facing the world today with >10 million new cases of cancer every year. The self-renewal, tumor-homing ability and low immunogenicity of mesenchymal stromal cells (MSCs) make them potential delivery candidates for suicide genes for anti-tumor therapy. However, unstable supply and short life span of adult MSCs in vitro have limited this therapeutic potential. In this study, we aimed to evaluate if immortalization of human fetal bone marrow-derived mesenchymal stromal cells by simian virus 40 (SV40-hfBMSCs) could be a stable source of MSCs for clinical application of suicide gene therapy. METHODS AND
RESULTS: Transduction of SV40 and herpes simplex virus thymidine kinase-IRES-green fluorescent protein (TK-GFP) did not cause significant change in the stem cell properties of hfBMSCs. The anti-tumor effect of SV40-TK-hfBMSCs in the presence of the prodrug ganciclovir was demonstrated in vitro and in nude mice bearing human prostate cancer cells, DU145 and PC3, which had been transduced with luciferase and GFP for imaging evaluation by an in vivo live imaging system (IVIS 200 imaging system; Caliper Life Sciences). Repeated injection of low doses (1 × 10(6) cells/kg) of SV40-TK-hfBMSCs was as effective as previously reported and did not cause observable harmful side effects in multiple organs. Mixed lymphocyte reaction showed that SV40-TK-hfBMSCs did not induce significant proliferation of lymphocytes isolated from healthy adults.
CONCLUSIONS: Taken together, immortalized hfBMSCs represent a reliable and safe source of MSCs for further clinical translational study.
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  fetal mesenchymal stromal cells; ganciclovir; prostate cancer; simian virus 40; thymidine kinase

Mesh:

Substances:

Year:  2013        PMID: 24199592     DOI: 10.1016/j.jcyt.2013.06.010

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  22 in total

Review 1.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

2.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

Review 3.  The future of stem cell therapy in hernia and abdominal wall repair.

Authors:  A H Petter-Puchner; R H Fortelny; S Gruber-Blum; H Redl; U Dietz
Journal:  Hernia       Date:  2014-08-14       Impact factor: 4.739

4.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Authors:  Paulina J Paszkiewicz; Simon P Fräßle; Shivani Srivastava; Daniel Sommermeyer; Michael Hudecek; Ingo Drexler; Michel Sadelain; Lingfeng Liu; Michael C Jensen; Stanley R Riddell; Dirk H Busch
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

5.  Randomized control trial of mesenchymal stem cells versus hyaluronic acid in patients with knee osteoarthritis - A Hong Kong pilot study.

Authors:  Kevin Ki-Wai Ho; Wayne Yuk-Wai Lee; James F Griffith; Michael Tim-Yun Ong; Gang Li
Journal:  J Orthop Translat       Date:  2022-10-06       Impact factor: 4.889

6.  The targeted inhibitory effects of human amniotic fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small cell lung carcinoma growth.

Authors:  L Li; S Li; T Cai; H Wang; X Xie; Z Liu; Y Zhang
Journal:  Gene Ther       Date:  2015-08-17       Impact factor: 5.250

7.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

Review 8.  Stem cell-based therapies for cancer treatment: separating hope from hype.

Authors:  Daniel W Stuckey; Khalid Shah
Journal:  Nat Rev Cancer       Date:  2014-09-01       Impact factor: 60.716

Review 9.  Improving the safety of cell therapy with the TK-suicide gene.

Authors:  Raffaella Greco; Giacomo Oliveira; Maria Teresa Lupo Stanghellini; Luca Vago; Attilio Bondanza; Jacopo Peccatori; Nicoletta Cieri; Sarah Marktel; Sara Mastaglio; Claudio Bordignon; Chiara Bonini; Fabio Ciceri
Journal:  Front Pharmacol       Date:  2015-05-05       Impact factor: 5.810

10.  A quantitative assessment of the content of hematopoietic stem cells in mouse and human endosteal-bone marrow: a simple and rapid method for the isolation of mouse central bone marrow.

Authors:  Maya M Mahajan; Betty Cheng; Ashley I Beyer; Usha S Mulvaney; Matt B Wilkinson; Marina E Fomin; Marcus O Muench
Journal:  BMC Hematol       Date:  2015-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.